BR112021024242A2 - Composições e métodos anti-psgl-1 para modular fenótipos inflamatórios de células mieloides e usos dos mesmos - Google Patents
Composições e métodos anti-psgl-1 para modular fenótipos inflamatórios de células mieloides e usos dos mesmosInfo
- Publication number
- BR112021024242A2 BR112021024242A2 BR112021024242A BR112021024242A BR112021024242A2 BR 112021024242 A2 BR112021024242 A2 BR 112021024242A2 BR 112021024242 A BR112021024242 A BR 112021024242A BR 112021024242 A BR112021024242 A BR 112021024242A BR 112021024242 A2 BR112021024242 A2 BR 112021024242A2
- Authority
- BR
- Brazil
- Prior art keywords
- psgl
- compositions
- methods
- myeloid cell
- cell phenotypes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/17—Monocytes; Macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Endocrinology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962857169P | 2019-06-04 | 2019-06-04 | |
| US201962867569P | 2019-06-27 | 2019-06-27 | |
| US201962947948P | 2019-12-13 | 2019-12-13 | |
| US202063032214P | 2020-05-29 | 2020-05-29 | |
| PCT/US2020/035702 WO2020247371A1 (en) | 2019-06-04 | 2020-06-02 | Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021024242A2 true BR112021024242A2 (pt) | 2022-04-26 |
Family
ID=73651973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021024242A BR112021024242A2 (pt) | 2019-06-04 | 2020-06-02 | Composições e métodos anti-psgl-1 para modular fenótipos inflamatórios de células mieloides e usos dos mesmos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12552873B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3980463A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7716992B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220042055A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114401990A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020288823A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021024242A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3141334A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL288510A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202110891A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020247371A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| KR20220042055A (ko) | 2019-06-04 | 2022-04-04 | 베르조 테라퓨틱스, 아이엔씨. | 골수성 세포 염증성 표현형을 조절하기 위한 항-psgl-1 조성물 및 방법, 그리고 이의 용도 |
| GB2584664B (en) * | 2019-06-10 | 2023-05-24 | Newcells Biotech Ltd | Improved retinal organoids and methods of making the same |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| US12682015B2 (en) * | 2021-03-03 | 2026-07-14 | International Business Machines Corporation | Ensemble voting classifiers using adjusted thresholds |
| JP2024540484A (ja) * | 2021-11-17 | 2024-10-31 | アルトゥルバイオ, インコーポレイテッド | 抗psgl-1抗体をjak阻害剤と組み合わせて使用してt細胞媒介性炎症性疾患またはがんを治療する方法 |
| CN116380755B (zh) * | 2023-03-20 | 2023-11-21 | 广州市第一人民医院(广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院) | CD127+PMN-MDSCs在诊断支气管肺发育不良中的应用及诊断试剂盒 |
| CN120682308B (zh) * | 2025-06-23 | 2025-12-02 | 北京昌盛鸿途生物科技有限公司 | 牛骨髓肽及其在提高免疫力中的应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL362227A1 (en) | 2000-03-24 | 2004-10-18 | Genetic Institute, Llc | A novel p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor |
| US7744888B2 (en) | 2001-08-03 | 2010-06-29 | Abgenomics Cooperatief U.A. | Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies |
| KR20060107501A (ko) * | 2003-06-30 | 2006-10-13 | 바이오-테크널러지 제너럴 (이스라엘) 리미티드 | 특이적인 인간 항체 |
| CA2561835A1 (en) | 2004-03-30 | 2005-10-13 | Den Kgl. Veterinaer-Og Landbohojskole | Improvements in cancer treatment and cancer treatment efficacy prediction by blocking and detecting protease inhibitors |
| MY148646A (en) * | 2004-05-10 | 2013-05-15 | Abgenomics Cooperatief Ua | Anti-psgl-1 antibodies |
| WO2007033959A2 (en) * | 2005-09-19 | 2007-03-29 | Vib Vzw | Use of p-selectin glycoprotein ligand 1 in modulation of hematogenous metastasis of lymphomas |
| US20110212096A1 (en) | 2006-12-01 | 2011-09-01 | Scott Rollins | Anti-p-selectin antibodies and methods of their use and identification |
| AU2009246166B2 (en) | 2008-05-15 | 2014-09-18 | Tetherex Pharmaceuticals Corporation | Anti-PSGL-1 antibodies and methods of identification and use |
| WO2011143411A1 (en) | 2010-05-12 | 2011-11-17 | Abt Holding Company | Modulation of splenocytes in cell therapy for traumatic brain injury |
| US20120130603A1 (en) | 2010-11-18 | 2012-05-24 | Sean Michael Simpson | System and method for controlling a transmission of a human-powered vehicle |
| EP3222635A1 (en) * | 2010-12-21 | 2017-09-27 | Selexys Pharmaceuticals Corporation | Anti-p-selectin antibodies and methods of their use and identification |
| EP2718325A4 (en) * | 2011-06-13 | 2015-03-11 | ABGENOMICS COöPERATIEF U A | ANTI-PSGL-1 ANTIBODIES AND USES THEREOF |
| KR102061358B1 (ko) | 2011-10-21 | 2019-12-31 | 트랜스진 에스.에이. | 대식세포 활성화의 조절 |
| WO2015077401A1 (en) | 2013-11-20 | 2015-05-28 | Drexel University | Compositions and methods for macrophage conversion |
| EP4079324A1 (en) * | 2014-07-08 | 2022-10-26 | Sanford-Burnham Medical Research Institute | Psgl-1 modulators and uses thereof |
| WO2016033527A1 (en) | 2014-08-29 | 2016-03-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunogenic modulation by endocrine deprivation therapy improves sensitivity of tumor cells to immune mediated lysis |
| US20160200815A1 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
| PE20190115A1 (es) | 2016-04-15 | 2019-01-16 | Immunext Inc | Anticuerpos vista antihumanos y su uso |
| GB201611535D0 (en) | 2016-07-01 | 2016-08-17 | King S College London | Methods and compositions for treating cancer with siglec-9 activity modulators |
| KR20250159733A (ko) | 2017-01-11 | 2025-11-11 | 브리스톨-마이어스 스큅 컴퍼니 | Psgl-1 길항제 및 그의 용도 |
| WO2020006385A2 (en) | 2018-06-29 | 2020-01-02 | Verseau Therapeutics, Inc. | Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof |
| KR20220042055A (ko) | 2019-06-04 | 2022-04-04 | 베르조 테라퓨틱스, 아이엔씨. | 골수성 세포 염증성 표현형을 조절하기 위한 항-psgl-1 조성물 및 방법, 그리고 이의 용도 |
-
2020
- 2020-06-02 KR KR1020217040138A patent/KR20220042055A/ko active Pending
- 2020-06-02 CA CA3141334A patent/CA3141334A1/en active Pending
- 2020-06-02 EP EP20818905.0A patent/EP3980463A4/en active Pending
- 2020-06-02 BR BR112021024242A patent/BR112021024242A2/pt unknown
- 2020-06-02 CN CN202080055123.9A patent/CN114401990A/zh active Pending
- 2020-06-02 TW TW109118529A patent/TW202110891A/zh unknown
- 2020-06-02 WO PCT/US2020/035702 patent/WO2020247371A1/en not_active Ceased
- 2020-06-02 AU AU2020288823A patent/AU2020288823A1/en not_active Abandoned
- 2020-06-02 JP JP2021571942A patent/JP7716992B2/ja active Active
- 2020-06-02 US US17/615,863 patent/US12552873B2/en active Active
-
2021
- 2021-11-29 IL IL288510A patent/IL288510A/en unknown
-
2025
- 2025-06-25 JP JP2025107222A patent/JP2025129213A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020247371A8 (en) | 2021-12-02 |
| JP2022535550A (ja) | 2022-08-09 |
| EP3980463A4 (en) | 2023-06-28 |
| US20220396632A1 (en) | 2022-12-15 |
| KR20220042055A (ko) | 2022-04-04 |
| JP7716992B2 (ja) | 2025-08-01 |
| TW202110891A (zh) | 2021-03-16 |
| JP2025129213A (ja) | 2025-09-04 |
| CA3141334A1 (en) | 2020-12-10 |
| AU2020288823A1 (en) | 2022-02-03 |
| US12552873B2 (en) | 2026-02-17 |
| IL288510A (en) | 2022-01-01 |
| CN114401990A (zh) | 2022-04-26 |
| EP3980463A1 (en) | 2022-04-13 |
| WO2020247371A1 (en) | 2020-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021024314A2 (pt) | Composições e métodos anti-siglec-9 para modular fenótipos inflamatórios de células mieloides e usos dos mesmos | |
| BR112021026181A2 (pt) | Composições anti-cd53 e métodos para modular fenótipos inflamatórios de células mieloides e usos dos mesmos | |
| BR112022023892A2 (pt) | Composições anti-vsig4 e métodos para modular fenótipos inflamatórios de células mieloides e seus usos | |
| WO2020247371A8 (en) | Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof | |
| BR112019001570A2 (pt) | terapias de combinação de receptores de antígeno quiméricos e inibidores de pd-1 | |
| SA520420518B1 (ar) | تبديل الانتحاء النسيجي للفَيروسات المُرتَبِط بالفَيروس الغُدِّيّ | |
| SA521421183B1 (ar) | بنيات جسم مضاد لكلودين 18.2 ومجموعة من التمايز 3 | |
| WO2018183888A3 (en) | Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling | |
| CR20210176A (es) | Anticuerpos estabilizadores de trem2 | |
| MX2017012939A (es) | Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19. | |
| EA201992610A1 (ru) | Экспансия -t-клеток, композиции и способы их применения | |
| PE20210005A1 (es) | Molecula de union al antigeno multiespecifica que tiene actividad de sustitucion de la funcion de cofactor del factor viii de coagulacion de sangre (fviii) y formulacion farmaceutica que contiene tal molecula como ingrediente activo | |
| MX2024011037A (es) | Ensamble de polipeptido quimerico y metodos para hacer y usar el mismo. | |
| BR112018070636A2 (pt) | método de tratamento de um sujeito humano que tem câncer, anticorpo, uso de um anticorpo, anticorpo para uso, combinação de um anticorpo, kit para uso no tratamento de câncer, composição farmacêutica, anticorpo biespecífico, método para tratamento de câncer, anticorpo biespecífico para uso e método de depleção de células t reguladoras em um tumor sólido em um sujeito | |
| MX349463B (es) | Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos. | |
| MX2025008949A (es) | Arni variante | |
| BR112017005390A2 (pt) | células citotóxicas alvo com receptores quiméricos para imunoterapia adotiva | |
| EA201491573A1 (ru) | Применение передающего сигнал домена cd2 в химерных антигенспецифических рецепторах второго поколения | |
| WO2018115017A3 (en) | CRYSTALLINE STRUCTURE OF GREMLIN-1 AND ANTIBODY INHIBITOR | |
| BR112014010532A2 (pt) | anticorpo e métodos para inibição seletiva de respostas de célula-t | |
| PH12021550254A1 (en) | Variant rnai against alpha-synuclein | |
| CL2023003554A1 (es) | Anticuerpos anti-sirp-alfa | |
| MX2021007692A (es) | Proteinas de union anti-pd-1 y metodos de uso de las mismas. | |
| BR112022009141A2 (pt) | Terapia contra tumores sólidos cd70+ usando células t geneticamente manipuladas visando cd70 | |
| Chambers et al. | LEM domain–containing protein 3 antagonizes TGFβ–SMAD2/3 signaling in a stiffness-dependent manner in both the nucleus and cytosol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |